Article
Oncology
Yaniv Berger, Mihai Giurcanu, Charles C. Vining, Darryl Schuitevoerder, Mitchell C. Posner, Kevin K. Roggin, Blase N. Polite, Chih-Yi Liao, Oliver S. Eng, Daniel V. T. Catenacci, Kiran K. Turaga
Summary: The study found that in patients receiving systemic chemotherapy, cytoreductive surgery (CRS) may be associated with longer overall survival compared to no surgery. Patients undergoing CRS were younger, had a lower proportion of disease involving multiple sites, and were more likely to have clinically occult disease.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Sivesh K. Kamarajah, Sheraz R. Markar, Alexander W. Phillips, George Salti, Fadi Dahdaleh, Ewen A. Griffiths
Summary: This study suggests that palliative gastrectomy may have a modest survival benefit over palliative chemotherapy for patients with metastatic gastric adenocarcinoma. Patients may benefit differently based on the site of metastasis, with better outcomes seen in liver, bone, and peritoneal metastases.
Article
Oncology
Xiaotian Zhang, Han Liang, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Zhaode Bu, Lin Chen, Yian Du, Xinbao Wang, Aiwen Wu, Guoli Li, Xiangqian Su, Gang Xiao, Ming Cui, Dan Wu, Li Chen, Xiaojiang Wu, Yanbing Zhou, Lianhai Zhang, Chengxue Dang, Yulong He, Zhongtao Zhang, Yihong Sun, Yong Li, Huanqiu Chen, Yuxian Bai, Changsong Qi, Peiwu Yu, Guanbao Zhu, Jian Suo, Baoqing Jia, Leping Li, Changming Huang, Fei Li, Yingjiang Ye, Huimian Xu, Xin Wang, Yannan Yuan, E. Jian-Yu, Xiangji Ying, Chen Yao, Lin Shen, Jiafu Ji
Summary: The study found that perioperative SOX treatment was more effective than adjuvant CapOx treatment in patients with locally advanced gastric cancer; adjuvant SOX treatment was non-inferior to adjuvant CapOx treatment in these patients, with similar safety profiles.
Article
Oncology
Alimu Dayimu, Lorena Di Lisio, Shubha Anand, Isart Roca-Carreras, Wendi Qian, Abdulrahman Al-Mohammad, Bristi Basu, Juan W. W. Valle, Duncan Jodrell, Nikos Demiris, Pippa Corrie
Summary: Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) has limited benefits and predicting response is challenging. This study found that patient performance status, tumor burden, plasma protein biomarkers, and circulating tumor DNA (ctDNA) are associated with treatment outcomes and overall survival in metastatic PDAC patients. Changes in plasma biomarkers can predict survival outcomes, while the role of ctDNA in guiding treatment needs further exploration.
BRITISH JOURNAL OF CANCER
(2023)
Article
Surgery
Pooja Prasad, Ashwin Sivaharan, Maziar Navidi, Bridget H. Fergie, S. Michael Griffin, Alexander W. Phillips
Summary: This study aimed to investigate the impact of neoadjuvant chemotherapy on the prognosis of patients with gastric adenocarcinoma. The results showed that the extent of pathological downstaging in patients who received neoadjuvant chemotherapy was associated with overall survival, and a downstaging of more than 3 stages was the strongest independent predictor of overall survival. Therefore, patients downstaged due to neoadjuvant chemotherapy may have better clinical outcomes.
Article
Multidisciplinary Sciences
Huang-Ming Hu, Hui-Jen Tsai, Hsiu-Ying Ku, Su-Shun Lo, Yan-Shen Shan, Hung-Chi Chang, Yee Chao, Jen-Shi Chen, Shu-Chen Chen, Chun-Ju Chiang, Anna Fen-Yau Li, Hsiu-Po Wang, Tsang-En Wang, Li-Yuan Bai, Ming-Shiang Wu, Li-Tzong Chen, Tsang-Wu Liu, Yi-Hsin Yang
Summary: Chemotherapy plus surgery may offer a survival benefit for selected patients with metastatic gastric adenocarcinoma. Age, year of diagnosis, tumor grade, and treatment modalities are significant prognostic factors for survival outcomes. The study highlights the importance of individualized treatment approaches for patients with this disease.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Joseph J. Zhao, Dominic Wei Ting Yap, Yiong Huak Chan, Benjamin Kye Jyn Tan, Chong Boon Teo, Nicholas L. Syn, Elizabeth C. Smyth, Yu Yang Soon, Raghav Sundar
Summary: By reconstructing Kaplan-Meier plots of PD-L1 CPS subgroups, this study found no significant benefit in adding immune checkpoint inhibitors to chemotherapy for low PD-L1-expressing gastroesophageal adenocarcinoma tumors.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ruiping Wang, Minghao Dang, Kazuto Harada, Guangchun Han, Fang Wang, Melissa Pool Pizzi, Meina Zhao, Ghia Tatlonghari, Shaojun Zhang, Dapeng Hao, Yang Lu, Shuangtao Zhao, Brian D. Badgwell, Mariela Blum Murphy, Namita Shanbhag, Jeannelyn S. Estrella, Sinchita Roy-Chowdhuri, Ahmed Adel Fouad Abdelhakeem, Yuanxin Wang, Guang Peng, Samir Hanash, George A. Calin, Xingzhi Song, Yanshuo Chu, Jianhua Zhang, Mingyao Li, Ken Chen, Alexander J. Lazar, Andrew Futreal, Shumei Song, Jaffer A. Ajani, Linghua Wang
Summary: The study investigated intratumoral heterogeneity (ITH) in peritoneal carcinomatosis of gastric cancer patients through single-cell transcriptome profiling, revealing significant correlations between ITH and patient survival. By analyzing the diversity in tumor cell lineage/state compositions, researchers identified a prognostic signature that could be practical for patient stratification.
Article
Biochemistry & Molecular Biology
Huafu Li, Chunming Wang, Linxiang Lan, Leping Yan, Wuguo Li, Ian Evans, E. Josue Ruiz, Qiao Su, Guangying Zhao, Wenhui Wu, Haiyong Zhang, Zhijun Zhou, Zhenran Hu, Wei Chen, Joaquim M. Oliveira, Axel Behrens, Rui L. Reis, Changhua Zhang
Summary: In this study, the researchers investigated the mechanism of oxaliplatin resistance in gastric cancer using in vitro human gastric cancer organoids and oxaliplatin-resistant cell lines, as well as in vivo tumorigenicity experiments. They found that CD133+ stem cell-like cells are the main subpopulation associated with resistance, and that the gene PARP1 plays a central role in mediating this resistance. The researchers discovered that PARP1 can effectively repair DNA damage caused by oxaliplatin by activating the base excision repair pathway, leading to the development of drug resistance. They also found that CD133+ cells exhibit increased expression of the mRNA modification N6-methyladenosine (m6A) and its writer METTL3, which enhances the stability of PARP1 and contributes to its DNA damage repair ability. Overall, this study demonstrates that m6A methyltransferase METTL3 promotes oxaliplatin resistance in CD133+ gastric cancer stem cells by increasing PARP1 mRNA stability and base excision repair activity.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Multidisciplinary Sciences
Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Madhavi Tripathi, Nishikant Avinash Damle, Shamim Ahmed Shamim, Rakesh Kumar, Amlesh Seth, Chandrasekhar Bal
Summary: This study focused on the long-term outcomes of mCRPC patients treated with Lu-177-PSMA-617 RLT. Results showed favorable efficacy with potential for prolonged survival, but further research on prognostic factors within the patient cohort is needed.
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Article
Oncology
Xiaohong Han, Zheng Wang, Lei Zhang, Yinchen Shen, Qiaoyun Tan, Yongkun Sun, Jianfei Wang, Xiaoyan Qian, Hongying Yang, Yuankai Shi
Summary: A three-stage study framework identified a stable association of rs6891545C > A polymorphism in the SLF1 gene with the response to oxaliplatin-based adjuvant chemotherapy in patients with stage II and III colon cancer, suggesting that patients carrying the A allele had better treatment response.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Sergio De La Torre, Yelena Y. Janjigian, Steven B. Maron, Geoffrey Y. Ku, Laura H. Tang, Pari M. Shah, Abraham Wu, David R. Jones, David B. Solit, Nikolaus Schultz, Karuna Ganesh, Michael F. Berger, Daniela Molena
Summary: MDM2 amplification and TP53 status are associated with response to therapy in patients with esophageal adenocarcinoma. Worsening TP53 dysfunction is directly correlated with worse treatment outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie Wilson, Sandra E. Fischer, George Zogopoulos, Faiyaz Notta, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O'Kane
Summary: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP, while no association was observed in patients receiving mFFX.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Sara Cherradi, Veronique Garambois, Johanna Marines, Augusto Faria Andrade, Alexandra Fauvre, Olivia Morand, Manon Fargal, Ferial Mancouri, Adeline Ayrolles-Torro, Nadia Vezzo-Vie, Marta Jarlier, Gerald Loussaint, Steve Huvelle, Nicolas Joubert, Thibault Mazard, Celine Gongora, Philippe Pourquier, Florence Boissiere-Michot, Maguy Del Rio
Summary: The expression of the tight junctional protein claudin 1 (CLDN1) in liver metastases of colorectal cancer (CRC) patients after chemotherapy was found to be significantly correlated with the histologic response to chemotherapy. Further experiments showed that conventional chemotherapies used in CRC treatment could induce CLDN1 expression, which was associated with resistance to apoptosis. Targeting chemotherapy-induced CLDN1 expression may represent a therapeutic opportunity to overcome resistance and improve the outcome of advanced CRC patients.
CELL AND BIOSCIENCE
(2023)
Article
Genetics & Heredity
Wu Jiang, Lin Li, Chuan-Feng Ke, Wei Wang, Bin-Yi Xiao, Ling-Heng Kong, Jing-Hua Tang, Yuan Li, Xiao-Dan Wu, Ying Hu, Wei-Hua Guo, Si-Zhen Wang, De-Sen Wan, Rui-Hua Xu, Zhi-Zhong Pan, Pei-Rong Ding
Summary: This study found that universal germline testing in patients with colorectal cancer can help identify potential hereditary cancer syndromes, especially in those under 70 years old. Enhanced surveillance and tailored treatment may be beneficial for patients with germline pathogenic variants.
JOURNAL OF MEDICAL GENETICS
(2022)
Article
Oncology
Shaohan Yin, Xiao Luo, Yadi Yang, Ying Shao, Lidi Ma, Cuiping Lin, Qiuxia Yang, Deling Wang, Yingwei Luo, Zhijun Mai, Weixiong Fan, Dechun Zheng, Jianpeng Li, Fengyan Cheng, Yuhui Zhang, Xinwei Zhong, Fangmin Shen, Guohua Shao, Jiahao Wu, Ying Sun, Huiyan Luo, Chaofeng Li, Yaozong Gao, Dinggang Shen, Rong Zhang, Chuanmiao Xie
Summary: This study developed a multi-scale cascaded convolutional network for brain metastasis detection and validated its accuracy. The results showed that using this system can improve the detection sensitivity of doctors and reduce reading time.
Article
Endocrinology & Metabolism
Yihui Chen, Michela Capello, Mayrim V. Rios Perez, Jody V. Vykoukal, David Roife, Ya'an Kang, Laura R. Prakash, Hiroyuki Katayama, Ehsan Irajizad, Alia Fleury, Sammy Ferri-Borgogno, Dodge L. Baluya, Jennifer B. Dennison, Kim-Anh Do, Oliver Fiehn, Anirban Maitra, Huamin Wang, Paul J. Chiao, Matthew H. G. Katz, Jason B. Fleming, Samir M. Hanash, Johannes F. Fahrmann
Summary: In this study, the researchers found that the high expression of intra-tumoral CES2 was significantly associated with poor overall survival in patients with PDAC. Knockdown of CES2 in PDAC cells inhibited cell growth and clonogenic capacity and attenuated tumor growth in a mouse model of PDAC. Furthermore, CES2 was found to promote metabolic changes through the activation of HNF4α. Targeting the CES2-sEH-HNF4α axis using CES2 or sEH inhibitors reduced cell viability in PDAC.
MOLECULAR METABOLISM
(2022)
Article
Multidisciplinary Sciences
Christophe Glorieux, Xiaojun Xia, Xin You, Zining Wang, Yi Han, Jing Yang, Gauthier Noppe, Christophe de Meester, Jianhua Ling, Annie Robert, Hui Zhang, Sheng-Ping Li, Huamin Wang, Paul J. Chiao, Li Zhang, Xiaobing Li, Peng Huang
Summary: This study investigated the impact of two common chemotherapy drugs, gemcitabine and cisplatin, on the therapeutic efficacy of PD-1 antibody in K-ras-driven cancers. The results showed that gemcitabine inhibits CD8+ T cell infiltration and antagonizes the therapeutic effect of PD-1 antibody, while cisplatin activates CD8+ T cells and shows synergistic activity with PD-1 antibody. Clinical data suggests that the combination of cisplatin and PD-1 antibody may be effective in advanced lung cancer patients with K-ras mutation.
JOURNAL OF ADVANCED RESEARCH
(2022)
Editorial Material
Oncology
Long Bai, Xiao-Luan Yan, Yun-Xin Lu, Qi Meng, Yu-Ming Rong, Liu-Fang Ye, Zhi-Zhong Pan, Bao-Cai Xing, De-Shen Wang
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Engineering, Chemical
Yeping Xie, Liufang Ye, Wenhua Chen, Pengju Liu, Yuansen Liu
Summary: This study demonstrates a method to convert waste cross-linked polyethylene (CLPE) cables into low-cost, high-strength, and all-weather electromagnetic interference (EMI) shielding materials. By utilizing selective heating mode of microwave and remaining cross-linked structure, a segregated structure with carbon nanotubes (CNTs) selectively enriched at the interfaces of the CLPE phases was successfully constructed, improving the electrical and EMI shielding properties of the composite material and exhibiting stable performance.
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
(2022)
Article
Multidisciplinary Sciences
Qi Zhao, Feng Wang, Yan-Xing Chen, Shifu Chen, Yi-Chen Yao, Zhao-Lei Zeng, Teng-Jia Jiang, Ying-Nan Wang, Chen-Yi Wu, Ying Jing, You-Sheng Huang, Jing Zhang, Zi-Xian Wang, Ming-Ming He, Heng-Ying Pu, Zong-Jiong Mai, Qi-Nian Wu, Renwen Long, Xiaoni Zhang, Tanxiao Huang, Mingyan Xu, Miao-Zheng Qiu, Hui-Yan Luo, Yu-Hong Li, Dong-Shen Zhang, Wei-Hua Jia, Gong Chen, Pei-Rong Ding, Li-Ren Li, Zheng-Hai Lu, Zhi-Zhong Pan, Rui-Hua Xu
Summary: Through ultradeep whole-exome sequencing, we identified 46 significantly mutated genes associated with CRC and proposed a subtyping strategy that classifies CRC patients into four genomic subtypes with distinct clinical characteristics. Additionally, we found that mitochondrial DNA copy number is an independent factor for predicting the survival outcome of CRCs.
NATURE COMMUNICATIONS
(2022)
Article
Genetics & Heredity
Zhen Zhang, Zi-Xian Wang, Yan-Xing Chen, Hao-Xiang Wu, Ling Yin, Qi Zhao, Hui-Yan Luo, Zhao-Lei Zeng, Miao-Zhen Qiu, Rui-Hua Xu
Summary: By analyzing single-cell RNA sequencing data from ICI-treated patients, it was found that cancer stemness may be associated with resistance to ICI treatment. The developed novel stemness signature (Stem.Sig) showed improved predictive performance for ICI response across multiple cancers, potentially serving as a competitive tool for patient selection in immunotherapy.
Article
Gastroenterology & Hepatology
Ting Li, Yue-Tao Tan, Yan-Xing Chen, Xiao-Jun Zheng, Wen Wang, Kun Liao, Hai-Yu Mo, Junzhong Lin, Wei Yang, Hai-Long Piao, Rui-Hua Xu, Huai-Qiang Ju
Summary: Methionine and YTHDF1 play a critical role in anticancer immunity through regulating the functions of T cells. Targeting methionine metabolism or YTHDF1 could be a potential new strategy for cancer immunotherapy.
Letter
Oncology
Rui Liu, Panpan Liu, Huichang Bi, Jianhua Ling, Huiqin Zhang, Mingquan Zhang, Yumin Hu, Paul J. Chiao, Peng Huang, Jinyun Liu
CANCER COMMUNICATIONS
(2023)
Article
Oncology
Xiao-Li Wei, Yang Zhang, Hong-Yun Zhao, Wen-Feng Fang, Hui-Yan Luo, Miao-Zhen Qiu, Ming-Ming He, Ben-Yan Zou, Jie Xie, Chun-Lei Jin, Xian-Feng Zhou, Feng Wang, Feng-Hua Wang, Yu-Hong Li, Zhi-Qiang Wang, Rui-Hua Xu
Summary: This report presents the results of two phase I trials evaluating the tolerability, safety, and preliminary antitumor activity of SHR7390 monotherapy and SHR7390 in combination with camrelizumab in patients with advanced solid tumors and treatment-refractory advanced or metastatic colorectal cancer (CRC).
Retraction
Cell Biology
Hong-En Yu, Feng Wang, Fang Yu, Zhao-Lei Zeng, Yun Wang, Yun-Xin Lu, Ying Jin, De-Shen Wang, Miao-Zhen Qiu, Heng-Ying Pu, Tie-Bang Kang, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu, Hui-Yan Luo
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Yi Han, Yan-Yu Zhang, Yi-Qian Pan, Xiao-Jun Zheng, Kun Liao, Hai-Yu Mo, Hui Sheng, Qi-Nian Wu, Ze-Xian Liu, Zhao-Lei Zeng, Wei Yang, Shu-Qiang Yuan, Peng Huang, Huai-Qiang Ju, Rui-Hua Xu
Summary: Interleukin-10 (IL-10) plays a role in inflammation and tumor progression, but its role in cancer is unclear. This study found that IL-10 stimulation leads to acetylation of nicotin-amide nucleotide transhydrogenase (NNT) in cancer cells, which induces the translocation of p300/CBP-associated factor (PCAF) to the mitochondria. This acetylation enhances NNT activity, increases NADPH production, and protects tumor cells from ferroptosis, contributing to tumor immune evasion.
Article
Oncology
Zeyi Guo, Qingyu Xie, Yanping Wu, Haiyu Mo, Jiajun Zhang, Guolin He, Zhongzhe Li, Luxiang Gan, Lei Feng, Ting Li, Yi Wang, Yu Fu, Lei Cai, Shao Li, Chao Yu, Yi Gao, Mingxin Pan, Shunjun Fu
Summary: This study reveals the role of a circular RNA molecule, circDHPR, in hepatocellular carcinoma (HCC). It affects tumor growth and metastasis by regulating the miR-3194-5p/RASGEF1B/Ras/MAPK signaling pathway, suggesting circDHPR as a potential biomarker and therapeutic target for HCC.
Article
Biochemistry & Molecular Biology
Jin-Fei Lin, Pei-Shan Hu, Yi-Yu Wang, Yue-Tao Tan, Kai Yu, Kun Liao, Qi-Nian Wu, Ting Li, Qi Meng, Jun-Zhong Lin, Ze-Xian Liu, Heng-Ying Pu, Huai-Qiang Ju, Rui-Hua Xu, Miao-Zhen Qiu
Summary: This study reveals the role and regulation mechanism of cysteine desulfurase (NFS1) in the sensitivity of colorectal cancer cells to oxaliplatin. Loss of NFS1 enhances the sensitivity of colorectal cancer cells to oxaliplatin and triggers PANoptosis by increasing intracellular levels of reactive oxygen species (ROS). In addition, high expression of NFS1 is associated with poor survival and chemoresistance in patients with colorectal cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)